), and gram-negative organisms accounted for 22% and 14% of all BSIs P ! .001 for these years, respectively. Neutropenia was observed in 30% of patients, so neutropenic and nonneutropenic patients were compared. In both, the predominant pathogens were coagulase-negative staphylococci (32% of isolates recovered from neutropenic patients and 30% of isolates recovered from nonneutropenic patients). The source of BSI was not determined for 57% of patients. The crude mortality rate was 36% for neutropenic patients and 31% for nonneutropenic patients.
Bloodstream infections (BSIs) are currently the 13th leading cause of death in the United States, and the age-adjusted mortality rate has increased by 78% during the past 2 decades [1] . Approximately 250,000 cases of nosocomial BSI occur annually in the United States [2] . The proportion of patients with nosocomial BSI who have an underlying malignancy is ∼10% (Surveillance unknown origin, the attack rate for BSI is 11%-38% [11] [12] [13] [14] .
The clinical manifestations of BSI in these patients may vary from transient bacteremia to fulminant septic shock. In adult patients with BSI and underlying malignancies, the crude mortality rate is 18%-42% [3, 8, 15, 16] . In the face of emerging multidrug-resistant organisms, antimicrobial prophylaxis and treatment have become increasingly difficult in these highly compromised patients. This study was conducted to assess the epidemiological features of BSI in adult patients with malignancies and the species distribution and antimicrobial susceptibilities of causative pathogens. In addition, patients who had neutropenia were compared with those who did not have neutropenia.
MATERIALS AND METHODS
Background. The SCOPE Project, based at Virginia Commonwealth University in Richmond, was established to identify the predominant pathogens and antimicrobial susceptibilities of nosocomial bloodstream isolates. The 49 participating hospitals throughout the United States represent medical institutions of various sizes (range, 60-1200 beds) from a broad range of geographical regions [9, 17] . The data generated by the SCOPE Project have shown a high correlation with data from the National Nosocomial Infection Surveillance (NNIS) program of the Centers for Disease Control and Prevention (Atlanta, GA) [17] .
Study design. Clinical data and bloodstream isolates were prospectively collected by local infection-control practitioners. Adult patients admitted during the period of 1 March 1995 through 28 February 2001 to one of the 49 hospitals participating in the SCOPE Project were eligible if they had an underlying malignancy and met the criteria for a nosocomial BSI. A nosocomial BSI was determined to have occurred if у1 culture of a blood sample obtained у48 h after admission to the hospital yielded a pathogenic organism. If the bloodstream isolate was a potential skin contaminant (e.g., diphtheroids, Propionibacterium species, Bacillus species, CoNS, or micrococci), all of the following criteria were required for the diagnosis: the presence of an intravascular catheter, the initiation of antimicrobial therapy, and у1 of the following: temperature of 138.0ЊC or !36.0ЊC, chills, and systolic blood pressure of !90 mm Hg [9] . Episodes of BSI that represented relapses were excluded. However, second episodes after different hospital admissions were included as separate cases. We studied the data for all eligible episodes of BSI.
The data that were routinely collected included age, sex, underlying malignancies, predisposing clinical conditions, species distribution and antimicrobial susceptibility of causative pathogens, and outcome. Sources of secondary BSI were identified by cultures of samples obtained from distant sites that yielded the same pathogen with an identical resistance pattern. Patients who had neutropenia (absolute neutrophil count [ANC], !1000 neutrophils/mL) at the onset of BSI were then compared with patients who had hematological malignancies but not neutropenia.
Microbiological methods. Blood cultures were processed at the participating hospitals. The identification of blood isolates and susceptibility testing were performed by the routine methods in use at the affiliated laboratories.
Statistical analysis. The results are expressed as the mean or as a proportion of the total number of patients value ‫ע‬ SD or isolates. For continuous variables, mean values were compared by 2-sample Student's t tests for independent samples. Differences in proportions were compared by x 2 test or Fisher's exact test, when appropriate. Mean values are reported ‫1ע‬ SD. All tests of significance are 2-tailed; a was set at 0.05. The Mann-Whitney U test was performed to test the equality of continuous variables. All statistical analyses were performed with use of SPSS software, version 10.0 for Windows (SPSS). ). Ventilator support before BSI P ! .001 was required for 27 (4%) and 118 (7%) of patients, respectively (OR, 1.9; 95% CI, 1.23-3.01;
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). P p .003 Microbiological features. During the study period, a total of 2711 isolates were recovered during 2340 episodes of BSI. Sixty-one percent of all episodes were caused by gram-positive aerobic organisms, and 27% were caused by gram-negative aerobic organisms. The proportion of gram-positive organisms was 62% for BSIs in 1995 and 76% for those in 2000 (P !
). The proportions of gram-negative pathogens during the .001 same periods of time were 22% and 15%, respectively. The greatest changes in the spectrum of pathogens occurred from 1999 to 2000. The proportion of gram-positive and gram-negative organisms changed from 60% to 76% and from 30% to 14% in those years, respectively. During that time, there were no significant differences in hospitals reporting to SCOPE. Also, proportions did not change significantly if only data from the hospitals that reported continuously for 1995-2000 were analyzed. Anaerobes were rarely isolated (3% of isolates), and the proportion remained stable throughout the study period. Fungi accounted for 10% of isolates, with a nadir of 6% in 1998 and a peak of 15% in 1995 (table 2) .
The organisms that were most frequently isolated from neutropenic patients were CoNS (32% of BSIs), S. aureus (12% of BSIs), E. coli (7% of BSIs), and enterococci (6% of BSIs). In nonneutropenic patients, the most common pathogens were CoNS (30% of BSIs), enterococci (14% of BSIs), and S. aureus (11% of BSIs). Candida species accounted for 9% and 8% of isolates recovered from neutropenic and nonneutropenic patients, respectively (table 3) . Viridans group streptococci, which accounted for 3% of all isolates in neutropenic patients, were significantly more common in this group (OR, 1.9; 95% CI, 1.87-7.60;
). Enterococcus faecium was more frequently P ! .001 isolated from patients without neutropenia than it was from patients with neutropenia (6% vs. 2%; OR, 3.0; 95% CI, 1.75-5.04;
). Other frequently isolated organisms were P ! .001 distributed almost equally in both groups. Enterococci were isolated earliest during the hospital stay (mean, day 10), whereas viridans group streptococci and Candida species were isolated latest in the hospital stay (mean, days 17 and 18, respectively). A total of 329 (14%) of all episodes were polymicrobial.
No significant seasonal or geographical patterns could be observed for any of the organisms when different time periods and geographical regions (the northwest, northeast, southwest, and southeast United States) were compared. Primary BSI, in which no source could be determined, was seen in 60% of nonneutropenic patients and in 56% of neutropenic patients. However, samples from distant sites were infrequently obtained for culture; therefore, some points of origin might not have been detected. Secondary BSI most often originated from intravenous catheters (in 24% of neutropenic patients and 27% of nonneutropenic patients) and the urinary tract (5% and 7%, respectively), followed by the lower respiratory tract and the gastrointestinal tract (4% and 3% each, respectively). No significant differences between neutropenic and nonneutropenic hosts were observed with regard to sources of infection. Antimicrobial susceptibility. Methicillin resistance was detected in 29% of S. aureus isolates and in 77% of CoNS isolates. Vancomycin resistance was found in 56% of E. faecium isolates.
Ceftazidime resistance was noted in 7% of P. aeruginosa isolates. Decreased susceptibility to penicillin (MIC, у0.12 mg/L) was detected in 27% of viridans group streptococci. Among Enterobacteriaceae, resistance to ceftriaxone was most common among Enterobacter isolates (42%). Imipenem resistance was observed in 6% of P. aeruginosa isolates and in 1% of Klebsiella isolates. Resistance to gentamicin was encountered in 15% of P. aeruginosa isolates, 5% of E. coli isolates, and 4% of Enterobacter isolates. Resistance rates of pathogens isolated from neutropenic hosts did not differ significantly from that for nonneutropenic hosts. However, for P. aeruginosa, resistance to ceftazidime was not detected in isolates recovered from patients with an ANC of !1000 neutrophils/mL, but it was observed in 9% of isolates recovered from patients with an ANC of у1000 neutrophils/mL ( ). Resistance to vancomycin was higher P p .2 in E. faecium isolates recovered from nonneutropenic patients, compared with isolates recovered from neutropenic patients (56% vs. 50%; ). P p .8 Outcome. Outcome data were available for all 2011 patients with monomicrobial BSI. The overall mortality rate was 32%, ranging from 16% in patients with BSI due to viridans group streptococci to 45% in patients with BSI due to Candida species. In general, the rates were higher for neutropenic patients than they were for nonneutropenic patients. The mortality rate for patients with BSI due to P. aeruginosa was 36% (48% of neutropenic vs. 31% of nonneutropenic patients;
); for E. coli, it was 35% (38% vs. 33%, respectively; P p .2 ); for vancomycin-resistant E. faecium, it was 34% (67% P p .6 vs. 29%, respectively; ); and for CoNS, it was 33% (34% P p .05 vs. 32%, respectively;
; table 4). P p .2 In patients with S. aureus BSI, there were no significant differences in outcome between patients with BSI due to methicillin-resistant strains, compared with those with BSI due to methicillin-susceptible strains (18% vs. 23% died, respectively; OR, 0.7; 95% CI, 0.34-1.52;
). However, because of the P p .4 limited number of patients in each group, the difference was not statistically significant (OR, 2.3; 95% CI, 0.88-5.99; P p ). For polymicrobial BSI, the outcome was worse for neu-.1 tropenic patients (38% died, compared with 27% of nonneutropenic patients; OR, 1.8; 95% CI, 1.2-2.6;
). P p .002
DISCUSSION
Patients with malignancies and neutropenia are at high risk for the development of nosocomial BSI. The attack rate of BSI in neutropenic patients is 11%-38% [12] [13] [14] and is particularly high in patients who have undergone bone marrow transplantation, with a reported rate of 360 BSIs per 1000 neutropenic episodes [3] . The proportion of BSIs caused by gram-positive organisms has increased considerably in recent years [9, [18] [19] [20] , and figures of 70%-81% have been reported [5, 21] . Confirming these studies, we also found that gram-positive organisms are the most prevalent pathogens in nosocomial BSIs in patients with malignancies in hospitals throughout the United States, ranging from 64% of BSIs in 1995 to 76% of BSIs in 2000. Others have reported that BSIs in patients with hematologic malignancies or solid tumors are most frequently caused by CoNS, viridans group streptococci, S. aureus, E. coli, and P. aeruginosa, in various rank orders [5] [6] [7] [8] .
Except for E. faecium, which was isolated more frequently from nonneutropenic patients, and viridans group streptococci, which were isolated more frequently from neutropenic patients, species distribution did not vary significantly between neutropenic and nonneutropenic hosts. It is of note that viridans group streptococci were isolated from only 3% of positive blood cultures of neutropenic patients in the present study. This pro-portion is lower than that reported previously from comparable patient populations (9%-30%) [5, [22] [23] [24] [25] [26] . The lower rate observed in our study might be in part attributable to the consideration of only nosocomial BSI in this study, as opposed to other studies, in which cultures of blood samples obtained at the time of admission were also included. In addition, our definition of neutropenia as an ANC of !1000 neutrophils/mL may also add to the low rate, because viridans group streptococcal bacteremia occurs more frequently in patients with hematologic malignancies, profound neutropenia, and severe mucositis than it does in patients with solid tumors and less-severe neutropenia.
CoNS were the most frequently isolated pathogens both in neutropenic and nonneutropenic hosts (32% and 30%, respectively). Other studies [3, [5] [6] [7] [8] reported proportions of BSIs due to CoNS of 10%-14%. The difference might be partially explained by the case definition of BSI used by the SCOPE Project. Even though strictly defined clinical signs are required for inclusion, patients with only 1 blood culture yielding CoNS are eligible. Recent studies have shown that the proportion of contaminants is lower if у2 positive blood cultures (with samples obtained within hours of each other) are required for inclusion [27] [28] [29] . Therefore, our design might lead to an overestimation of the prevalence of BSIs due to CoNS. However, this should be minimized by the strict clinical definitions used in the SCOPE Project to ascertain the clinical relevance of the positive blood culture. In addition, data from the SCOPE Project have shown a high correlation with the NNIS data [17] . Mrázová-Studená and colleagues [30] reported a significantly higher frequency of anaerobic and fungal BSI in neutropenic patients who had cancer, compared with nonneutropenic patients who had cancer. We also found that anaerobic bacteria were more prevalent among neutropenic patients. However, concurring with the results of the Club d'Etudes des Maladies Infectieuses en Cancer (CEMIC) group [31] , we could not detect any significant differences between neutropenic and nonneutropenic hosts with regard to the prevalence of fungi as causative pathogens of BSI. In contrast, P. aeruginosa infection was not significantly more common in either group in our study. However, a comparison of results is difficult because of a considerable variability in the patient populations investigated in different studies, even if only neutropenic patients are taken into account.
BSI in immunocompetent hosts often derives from dissemination of previously localized infections. In contrast, BSI in neutropenic patients is more likely to derive from endogenous sources, such as the gastrointestinal tract [26] . With regard to identified sources of BSI, we did not observe any significant differences in neutropenic versus nonneutropenic patients. However, sources were not determined for more than one-half of the patients in both groups, and some potential sources of infection that are important in neutropenic patients, such as the gastrointestinal tract, could not be assessed.
The resistance to methicillin among isolates of S. aureus was higher than in this study that in northern Europe [32] but comparable to resistance rates reported in other series from the United States [9] . However, compared with the overall population (all BSIs recorded by SCOPE), the rates were still relatively low (29% in the present study vs. 40% for all BSIs recorded by SCOPE). The prevalence of resistance to vancomycin in E. faecium in our study was comparable to that noted in recent studies from the United States [9] but higher than in recent European studies [31] . Increasing resistance to penicillin and other b-lactam antibiotics has been documented in viridans group streptococci isolated from neutropenic patients with cancer [26, 33] . Similar to data reported from a recent series from Germany [26] , we found that 73% of isolates were susceptible to penicillin. Resistance was observed in 13% of patients, a rate still lower than those reported from Spain [33] . Several recent studies found that neutropenia was independently associated with vancomycin-resistant enterococcal infection when comparing patients who had vancomycin-resistant enterococcal BSI with those who had vancomycin-susceptible enterococcal BSI [34, 35] . In contrast, Lucas et al. [36] , when comparing BSIs due to vancomycin-susceptible and -resistant enterococci, did not find neutropenia to be a risk factor for BSI due to vancomycin-resistant enterococci. In our series, the prevalence of resistance to vancomycin among isolates of E. faecium was higher in nonneutropenic patients, but the difference did not reach statistical significance.
One limitation of our study is that several factors that might have influenced the epidemiology of causative pathogens and outcome in neutropenic patients with BSI (such as depth and duration of neutropenia; presence of lymphopenia; type and stage of underlying malignancy; and incidence, severity, and duration of mucositis) could not be assessed, making comparison with other studies difficult. Also, because this study only included nosocomial BSIs, comparison with studies that have included patients who had community-acquired infections may be difficult. Recent studies involving neutropenic patients in the intensive care unit who have BSI reported crude mortality rates of 35%-83% [13, 37] , and the crude mortality rate for neutropenic patients with BSI is 18%-42% [3, 38] . In our series, the crude mortality rate was 35% in neutropenic patients and 31% in nonneutropenic patients. In contrast, Elting et al. [39] reported that BSI in neutropenic patients usually has a more benign course and is successfully treated in 190% of cases. Increased mortality rates for immunocompromised patients were found to be associated with BSI due to E. coli or P. aeruginosa, with mortality rates of 22%-33% [7] , and with BSI due to viridans group streptococci and enterococci (30% and 33%, respectively [7] ). In our study, outcome was worst for patients with monomicrobial BSI due to Candida species (crude mortality rate, 45%), followed by P. aeruginosa, E. coli, and vancomycin-resistant E. faecium. Of note, the mortality rate was also high for patients with BSI due to CoNS. When outcomes stratified by organism were compared between neutropenic and nonneutropenic hosts, no significant differences were seen. However, despite the large number of patients included in this study, the number of cases in some subsets was low. Therefore, further studies with a larger number of patients might be warranted.
In conclusion, we report an ongoing trend toward grampositive BSI and emerging and increasing resistance to antimicrobial agents in S. aureus, enterococci, and streptococci in patients with hematological malignancies and solid neoplasms in a large sample of hospitals across the United States.
